ClinicalTrials.gg
CompletedNCT06041438Updated Jun 3, 2026Results posted

A Study in Healthy Men to Test Whether Itraconazole Influences the Amount of BI 1584862 in the Blood

A Phase 1 interventional study of BI 1584862 and Itraconazole in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in Germany. Open to male participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Male
01

Study summary

The main objective of this trial is to investigate the effect on the exposure of BI 1584862 in plasma when given as single dose together with multiple doses of itraconazole (Test, T) as compared to BI 1584862 when given alone as oral single dose (Reference, R).

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead (ECG), and clinical laboratory tests
  2. Age of 18 to 50 years (inclusive)
  3. (BMI) of 18.5 to 29.9 kg/m2 (inclusive)
  4. Signed and dated written in accordance with ICH-GCP and local legislation prior to admission to the trial

Exclusion criteria

Exclusion Criteria:

  1. Any finding in the medical examination (including BP, PR or ) deviating from normal and assessed as by the investigator
  2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the range of 45 to 90 bpm
  3. Any laboratory value outside the reference range that the investigator considers to be of clinical relevance
  4. Any evidence of a concomitant disease assessed as clinically relevant by the investigator
  5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  6. Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
  7. Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
  8. History of relevant orthostatic hypotension, fainting spells, or blackouts Further exclusion criteria apply
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    BI 1584862 (R), then BI 1584862 + itraconazole (T)

    Reference treatment (R): healthy male subjects were administered one single dose of BI 1584862 as tablets orally with 240 milliliter (mL) of water after an overnight fast of at least 10 hours (h). Test treatment (T): healthy male subjects were administered one single dose of BI 1584862 as tablets orally with 240 mL of water after an overnight fast of at least 10 h. Additionally, subjects were administered one daily dose of 200 milligram (mg) itraconazole as an oral solution after an overnight fast of at least 9 h for several consecutive days. The two administrations of BI 1584862 were separated by a washout period.

    Drug: BI 1584862 · Drug: Itraconazole

Interventions

  • One dose with 240 mL of water after an overnight fast of at least 10 h

  • 200 mg daily after an overnight fast of at least 9 h for several consecutive days

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-time Curve of BI 1584862 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

    Area under the concentration-time curve of BI 1584862 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: 'subjects' was considered as a random effect, 'treatment' as a fixed effect. These quantities were then back-transformed to the original scale.

    Time frame: Within 3 to 4 h before and up to 3 days after BI 1584862 administration.

  2. Maximum Measured Concentration of BI 1584862 in Plasma (Cmax)

    Maximum measured concentration of BI 1584862 in plasma (Cmax) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: 'subjects' was considered as a random effect, 'treatment' as a fixed effect. These quantities were then back-transformed to the original scale.

    Time frame: Within 3 to 4 h before and up to 3 days after BI 1584862 administration.

Secondary outcomes

  1. Area Under the Concentration-time Curve of BI 1584862 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

    Area under the concentration-time curve of BI 1584862 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: 'subjects' was considered as a random effect, 'treatment' as a fixed effect. These quantities were then back-transformed to the original scale.

    Time frame: Within 3 to 4 h before and up to 3 days after BI 1584862 administration.

07

Results

Posted Jun 3, 2026

Participant flow

This was an open-label, two-period, two-treatment, fixed sequence design trial in healthy male subjects to investigate the effect of itraconazole on the pharmacokinetics of BI 1584862. The trial compared the test treatment (T, BI 1584862 given together with itraconazole) to the reference treatment (R, BI 1584862 given alone) using the fixed sequence R-T.

Reference treatment (R)
Participant flow — Reference treatment (R)
MilestoneBI 1584862 (R), Then BI 1584862 + Itraconazole (T)
Started14
Treated14
Completed14
Not completed0
Test treatment (T)
Participant flow — Test treatment (T)
MilestoneBI 1584862 (R), Then BI 1584862 + Itraconazole (T)
Started14
Treated14
Completed14
Not completed0

Outcome measures

PrimaryArea Under the Concentration-time Curve of BI 1584862 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area under the concentration-time curve of BI 1584862 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an analysis of variance (ANOVA) model on the logarithmic scale. The pharmacokinetic (PK) endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: 'subjects' was considered as a random effect, 'treatment' as a fixed effect. These quantities were then back-transformed to the original scale.

Time frame:
Within 3 to 4 h before and up to 3 days after BI 1584862 administration.
Reported as:
Geometric least squares mean · hour*nanomole/Liter
Area Under the Concentration-time Curve of BI 1584862 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
hour*nanomole/LiterBI 1584862 (R)BI 1584862 + Itraconazole (T)
Area Under the Concentration-time Curve of BI 1584862 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)999.27 ± NA7981.53 ± NA
Statistical analysis
  • BI 1584862 (R) vs BI 1584862 + Itraconazole (T) · Ratio of adjusted geometric means [%]: 798.74 · 90% CI 688.62 to 926.46Ratio \[%\] = (adjusted geometric mean of test treatment / adjusted geometric mean of reference treatment)\*100. Intra-individual geometric coefficient of variation (gCV) \[%\] = 22.4
PrimaryMaximum Measured Concentration of BI 1584862 in Plasma (Cmax)

Maximum measured concentration of BI 1584862 in plasma (Cmax) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: 'subjects' was considered as a random effect, 'treatment' as a fixed effect. These quantities were then back-transformed to the original scale.

Time frame:
Within 3 to 4 h before and up to 3 days after BI 1584862 administration.
Reported as:
Geometric least squares mean · nanomole/Liter
Maximum Measured Concentration of BI 1584862 in Plasma (Cmax)
nanomole/LiterBI 1584862 (R)BI 1584862 + Itraconazole (T)
Maximum Measured Concentration of BI 1584862 in Plasma (Cmax)408.11 ± NA801.07 ± NA
Statistical analysis
  • BI 1584862 (R) vs BI 1584862 + Itraconazole (T) · Ratio of adjusted geometric means [%]: 196.29 · 90% CI 174.54 to 220.75Ratio \[%\] = (adjusted geometric mean of test treatment / adjusted geometric mean of reference treatment)\*100. Intra-individual geometric coefficient of variation (gCV) \[%\] = 17.7
SecondaryArea Under the Concentration-time Curve of BI 1584862 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)

Area under the concentration-time curve of BI 1584862 in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz) is reported. Geometric least square mean (adjusted geometric mean) and adjusted geometric standard error were calculated using an ANOVA model on the logarithmic scale. The PK endpoints were log-transformed (natural logarithm) prior to fitting the ANOVA model, which included effects accounting for the following sources of variation: 'subjects' was considered as a random effect, 'treatment' as a fixed effect. These quantities were then back-transformed to the original scale.

Time frame:
Within 3 to 4 h before and up to 3 days after BI 1584862 administration.
Reported as:
Geometric least squares mean · hour*nanomole/Liter
Area Under the Concentration-time Curve of BI 1584862 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
hour*nanomole/LiterBI 1584862 (R)BI 1584862 + Itraconazole (T)
Area Under the Concentration-time Curve of BI 1584862 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)984.30 ± NA7825.12 ± NA
Statistical analysis
  • BI 1584862 (R) vs BI 1584862 + Itraconazole (T) · Ratio of adjusted geometric means [%]: 794.99 · 90% CI 685.35 to 922.18Ratio \[%\] = (adjusted geometric mean of test treatment / adjusted geometric mean of reference treatment)\*100. Intra-individual geometric coefficient of variation (gCV) \[%\] = 22.4

Adverse events

Collected over Adverse events (AEs): from drug administration and/or residual effect period (REP), up to 7 days. Deaths: from drug administration up to 17 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BI 1584862 (R)0/14 (0%)0/14 (0%)0/14 (0%)
Itraconazole Before BI 1584862 (ITZ-1, T)0/14 (0%)0/14 (0%)3/14 (21.4%)
Itraconazole + BI 1584862 (ITZ+BI, T)0/14 (0%)0/14 (0%)1/14 (7.1%)
Itraconazole + BI 1584862 (ITZ-2, T)0/14 (0%)0/14 (0%)1/14 (7.1%)
Most frequent other events
Most frequent other events
EventBI 1584862 (R)Itraconazole Before BI 1584862 (ITZ-1, T)Itraconazole + BI 1584862 (ITZ+BI, T)Itraconazole + BI 1584862 (ITZ-2, T)
Abdominal painGastrointestinal disorders0/141/140/140/14
PyrexiaGeneral disorders0/141/140/140/14
NasopharyngitisInfections and infestations0/140/140/141/14
Oral herpesInfections and infestations0/141/140/140/14
ArthralgiaMusculoskeletal and connective tissue disorders0/140/141/140/14
Back painMusculoskeletal and connective tissue disorders0/141/140/140/14

Baseline characteristics

Treated set (TS): the treated set included all subjects who were treated with at least 1 dose of trial drug.

Age, Continuous
Age, Continuous(Years)BI 1584862 (R), Then BI 1584862 + Itraconazole (T)
Mean32.4 ± 6.6
Sex: Female, Male
Sex: Female, Male(Participants)BI 1584862 (R), Then BI 1584862 + Itraconazole (T)
Female0
Male14
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BI 1584862 (R), Then BI 1584862 + Itraconazole (T)
Hispanic or Latino0
Not Hispanic or Latino14
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BI 1584862 (R), Then BI 1584862 + Itraconazole (T)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White13
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Humanpharmakologisches Zentrum Biberach
    Biberach, 88397, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2023 to primary completion in Nov 2023, 1 month.

Results were first posted in Jun 2026, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2023
First posted
Sep 18, 2023
StartActual
Sep 29, 2023
Primary completionActual
Nov 10, 2023
CompletionActual
Nov 10, 2023
Results first posted
Jun 3, 2026
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06041438
Responsible party
Sponsor
First posted
Sep 18, 2023
Start date
Sep 29, 2023
Primary completion
Nov 10, 2023
Completion
Nov 10, 2023
Results posted
Jun 3, 2026
Last update
Jun 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BI 1584862

Start the discussion